Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Acurx enrolled the first patient in PATHFINDER, a Phase 2 study of ibezapolstat in multiply recurrent C. difficile infection, with no results yet. The trial will assess clearing infection and reducing repeat episodes; management also reiterated plans for Phase 3 ASPIRE versus vancomycin subject to funding.
Acurx enrolled the first patient in PATHFINDER, a fully funded ~20-patient Phase 2 open-label rCDI study of ibezapolstat intended to support a potential NDA based on a single Phase 3 trial. A larger non-inferiority Phase 3 (ASPIRE) is planned subject to funding.Material DetailsContext by AI Analyst…